Pfizer vaccine price move in US could add $3bn to annual revenues       

The drugmaker is attempting to as much as quadruple its current US prices
Pfizer vaccine price move in US could add $3bn to annual revenues       

Pfizer said that it is targeting a range of $110 to $130 per dose for its Covid-19 vaccine once the US moves to a commercial market next year.

Pfizer's attempt to as much as quadruple its current US prices for its Covid-19 vaccines could spur revenues for years, analysts said.

The drugmaker, which developed and sells the vaccine with Germany's BioNTech, said that it is targeting a range of $110 to $130 a dose for the vaccine once the US moves to a commercial market next year.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited